Display Options:
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dopamine D2 receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Dyspepsia; Psychomotor Agitation; Psychotic Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Glucagon receptor agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: GABA-B receptor 1 agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Gastroesophageal Reflux
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Adenosine A2a receptor agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Pulmonary Disease, Chronic Obstructive
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cannabinoid CB1 receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Serine/threonine protein phosphatase 2A, catalytic subunit, alpha isoform inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Myelodysplastic Syndromes; Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Oligodendroglioma
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Multiple Sclerosis, Chronic Progressive; Colorectal Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Hepatitis C virus serine protease, NS3/NS4A inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hepatitis C, Chronic
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Tyrosine-protein kinase SYK inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Immune System Diseases; Leukemia, Myeloid, Acute; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Sjogren's Syndrome
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Alzheimer Disease; Cognitive Dysfunction; Schizophrenia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Breast Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Glutamate receptor ionotropic AMPA antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Insulin receptor inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Progesterone receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Breast Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA disrupting agent
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: HIV Infections
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Tubulin stabiliser
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Non-Small-Cell Lung
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Phosphodiesterase 3 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Intermittent Claudication
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Calcitonin gene-related peptide type 1 receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Migraine Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: P2X purinoceptor 7 antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Depressive Disorder, Major
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Metabotropic glutamate receptor 2 positive allosteric modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Perceptual Disorders; Depressive Disorder, Major; Schizophrenia; Seizures
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Anandamide amidohydrolase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Child Development Disorders, Pervasive; Phobic Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: C-C chemokine receptor type 2 antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Diabetes Mellitus, Type 2
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Neuronal acetylcholine receptor protein alpha-7 subunit positive allosteric modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Schizophrenia; Depressive Disorder; Smoking Cessation
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Histamine H3 receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Rhinitis, Allergic, Seasonal
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dopamine D2 receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Schizophrenia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Epilepsy, Reflex
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Serotonin 7 (5-HT7) receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Bipolar Disorder; Depressive Disorder, Major
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Rhinitis, Allergic, Seasonal
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Ephrin type-B receptor 4 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Colonic Neoplasms; Neoplasms; Ovarian Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Kinesin-like protein 1 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Liver Neoplasms; Melanoma; Ovarian Neoplasms; Prostatic Neoplasms; Rectal Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Renal Cell; Anemia, Sickle Cell; Renal Insufficiency, Chronic; Severe Acute Respiratory Syndrome
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 activator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Heart Failure; Shock